Table 1.
Patient Characteristics at Index Date
| Parameter | Patients With SZ (n = 8174) |
Patients With BD-I (n = 9142) |
|---|---|---|
| Sex, n (%) | ||
| Female | 5037 (61.6) | 6604 (72.2) |
| Race, n (%)a | ||
| White | 5554 (80.9) | 7036 (89.7) |
| Black | 1235 (18.0) | 770 (9.8) |
| Other | 75 (1.1) | 37 (0.5) |
| Age at index, mean (SD), years | 57.4 (17.7) | 48.2 (15.3) |
| Age category at index, n (%), years | ||
| 18–24 | 354 (4.3) | 634 (6.9) |
| 25–34 | 656 (8.0) | 1359 (14.9) |
| 35–44 | 908 (11.1) | 1680 (18.4) |
| 45–54 | 1515 (18.5) | 2111 (23.1) |
| 55–64 | 1788 (21.9) | 1942 (21.2) |
| ≥ 65 | 2953 (36.1) | 1416 (15.5) |
| Insurance type, n (%)b | ||
| Commercial | 2781 (40.4) | 3677 (51.1) |
| Medicaid | 773 (11.2) | 939 (13.1) |
| Medicare | 2392 (34.7) | 1742 (24.2) |
| Multiple | 909 (13.2) | 775 (10.8) |
| Other | 31 (0.5) | 59 (0.8) |
| Comorbidities, n (%)c | ||
| Depression | 4208 (51.5) | 4883 (53.4) |
| Anxiety disorders | 3988 (48.8) | 5142 (56.2) |
| Chronic pulmonary disease | 3597 (44.0) | 3943 (43.1) |
| Diabetes without chronic complications | 2253 (27.6) | 1787 (19.5) |
| Cerebrovascular disease | 1884 (23.0) | 1093 (12.0) |
| Congestive heart failure | 1132 (13.8) | 615 (6.7) |
| Peripheral vascular disease | 1048 (12.8) | 623 (6.8) |
| Myocardial infarction | 592 (7.2) | 389 (4.3) |
| Current tobacco use | 3667 (44.9) | 4442 (48.6) |
| Weight, mean (SD), kg | 85.05 (23.5) | 87.55 (24.1) |
| BMI category, n (%)d | ||
| < 18.5 kg/m2 | 168 (2.1) | 142 (1.6) |
| 18.5–24.9 kg/m2 | 1968 (24.3) | 1924 (21.1) |
| 25.1–29.9 kg/m2 | 2277 (28.1) | 2425 (26.6) |
| ≥ 30.0 kg/m2 | 3690 (45.5) | 4619 (50.7) |
| SGA treatment, n (%) | ||
| Olanzapine | 1513 (18.5) | 1564 (17.1) |
| Clozapine | 236 (2.9) | N/A |
| Iloperidone | 38 (0.5) | N/A |
| Paliperidone | 193 (2.4) | N/A |
| Risperidone | 2246 (27.5) | 1633 (17.9) |
| Quetiapine | 4038 (49.4) | 5935 (64.9) |
| Olanzapine/fluoxetine combination | N/A | 69 (0.8) |
aTotal n = 6864 for SZ, n = 7843 for BD-I
bTotal n = 6886 for SZ, n = 7192 for BD-I
cThe 3 comorbidities with the highest prevalence for each patient cohort (depression, anxiety disorders, and chronic pulmonary disease) are shown, in addition to select other cardiovascular and diabetes comorbidities
dTotal, n = 8103 for SZ, n = 9110 for BD-I
BD-I, bipolar I disorder; BMI, body mass index; N/A, not applicable; SD, standard deviation; SZ, schizophrenia